Compare CVV & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVV | IGC |
|---|---|---|
| Founded | 1982 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 32.0M |
| IPO Year | 2007 | 2005 |
| Metric | CVV | IGC |
|---|---|---|
| Price | $3.83 | $0.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 48.0K | ★ 573.5K |
| Earning Date | 11-09-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.86 | ★ 59.09 |
| EPS | ★ 1.58 | N/A |
| Revenue | ★ $41,128,639.00 | $1,271,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.55 | ★ N/A |
| Revenue Growth | ★ 96.27 | N/A |
| 52 Week Low | $2.96 | $0.08 |
| 52 Week High | $9.10 | $0.45 |
| Indicator | CVV | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 35.78 | 18.22 |
| Support Level | $3.74 | N/A |
| Resistance Level | $4.44 | $0.31 |
| Average True Range (ATR) | 0.20 | 0.02 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 36.90 | 54.35 |
CVD Equipment Corp designs, develops, and manufactures a broad range of equipment used to develop and produce materials and coatings for the aerospace, compound semiconductor, semiconductor, aerospace, battery energy storage markets as well as industrial applications, and research. It currently conducts its business through two reportable segments: CVD Equipment, which designs and manufactures chemical vapor deposition, physical vapor transport and thermal process equipment; and SDC, which designs and manufactures ultra-high purity gas and chemical delivery control systems. Its target markets are aerospace & defense and industrial, microelectronics / high power electronics, and EV battery materials / energy storage.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.